Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

heart failure/febbre

Il collegamento viene salvato negli appunti
12 risultati

Corticotropin releasing factor antagonists

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention relates to the treatment of certain conditions using a compound of formula I or II, or a pharmaceutically acceptable salt thereof, as defined below. Specifically, the compounds of formulas I and II, and their pharmaceutically acceptable salts, as

Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION The present invention relates to acetylenic aryl sulfonate hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinases (MMP), to processes for the preparation of such compounds, and to pharmaceutical compositions comprising such

Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION The present invention relates to acetylenic aryl sulfonate hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinases (MMP), to processes for the preparation of such compounds, and to pharmaceutical compositions comprising such

Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

Agents for preventing and treating disorders involving modulation of the RyR receptors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION This invention relates to novel compounds and their use to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. More particularly, the invention discloses compounds that are related to

Agents for preventing and treating disorders involving modulation of the RyR receptors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION This invention relates to novel compounds and their use to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. More particularly, the invention discloses compounds that are related to

Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors

Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION This invention relates to allenic aryl sulfonamide hydroxamic acids which act as inhibitors of TNF-.alpha. converting enzyme (TACE) and matrix metalloproteinase (MMP). The compounds of the present invention are useful in disease conditions mediated by MMP and TACE, such as
Unisciti alla nostra
pagina facebook

Il database di erbe medicinali più completo supportato dalla scienza

  • Funziona in 55 lingue
  • Cure a base di erbe sostenute dalla scienza
  • Riconoscimento delle erbe per immagine
  • Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
  • Leggi le pubblicazioni scientifiche relative alla tua ricerca
  • Cerca le erbe medicinali in base ai loro effetti
  • Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti

Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate

Google Play badgeApp Store badge